阿尔茨海默病的表观基因组剖析确定了因果变异,并揭示了表观基因组侵蚀
Xushen Xiong1, Benjamin T James2, Carles A Boix2
1Computer Science and Artificial Intelligence Lab, Massachusetts Institute of Technology, 32 Vassar St, Cambridge, MA 02139, USA; Liangzhu Laboratory, Zhejiang University, 1369 West Wenyi Road, Hangzhou 311121, China.
Cell
|September 29, 2023
概括
阿尔茨海默病 (AD) 风险位与微质增强剂和特定的转录因子有关. 晚期阿尔茨海默病的大脑表现出广泛的表观基因组失调,表明细胞身份丧失.
科学领域:
- 神经科学
- 基因组学
- 表观遗传学
背景情况:
- 已确定与阿尔茨海默病 (AD) 风险相关的数十个非编码位点.
- 导致AD风险的精确机制和转录调节回路仍然不太清楚.
研究的目的:
- 构建大脑规律的综合地图,详细说明表观基因概况,转录调节器和细胞类型特定的调节网络.
- 识别和优先考虑阿尔茨海默病 (AD) 变种的调节回路.
主要方法:
- 从92个个体 (具有和没有AD) 的85万个核进行表观基因组和转录基因组的概况.
- 使用峰值与基因链接开发多式数据集成和监管模块检测的新方法.
- 识别细胞类型特定的ATAC-QTL位点并将它们与峰值-基因链接集成.
主要成果:
- 阿尔茨海默病 (AD) 风险位显著富含微质增强剂,并与特定的转录因子 (SPI1,ELF2,RUNX1) 相关.
- 检测到9628个细胞类型特定的ATAC- QTL位点,并对AD变异调节回路进行优先排序.
- 在质细胞 (晚期AD) 和神经元 (早期AD) 中观察到不同的调节模块可访问性.
- 晚期阿尔茨海默病的大脑显示全球表观基因组失调,表明表观基因组侵蚀和细胞身份丧失.
结论:
- 这项研究提供了大脑规律的详细地图,强调了微质增强剂和特定转录因子在阿尔茨海默病 (AD) 发病过程中的作用.
- 表观基因失调和细胞身份丧失是晚期阿尔茨海默病 (AD) 的突出特征.
- 了解细胞类型特定的调节回路对于破译阿尔茨海默病 (AD) 机制至关重要.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


